Healthcare Meta ad transparency in India (2026): what Meta Ad Library actually shows, what it does not, and where honest inference fills the gap

Meta ad transparency in Indian healthcare is a subject buyers usually get either oversold or dismissed. Vendors imply you can see almost everything; competitors mutter that you can see almost nothing. The honest picture is in between and worth mapping carefully because your entire competitive-intelligence budget rides on knowing exactly which numbers are visible, which are inferred, and which will always sit inside your competitor's account. This piece walks through the Meta Ad Library surface as it exists in India in 2026, what changed with the 2019 political-ad reforms and later commercial expansion, what PrismSpy layers on top through structured tracking and defensible inference, and — critically — the ethical and DPDP Act 2023 lines we deliberately do not cross. If you run healthcare Meta ads or evaluate the tools that watch competitors, read this before your next tool purchase.

What the Meta Ad Library actually shows for Indian commercial ads

The Meta Ad Library is Meta's public disclosure surface for every ad currently running (and, in many cases, past ads) across Facebook and Instagram. For commercial ads in India — the category almost all healthcare ads fall under — the library shows a defined set of fields, and any tool claiming more is either inferring or fabricating.

You can see, per ad: the advertising Page name and verification status, the ad creative in full (image, video, carousel, Reel), the ad copy, the destination URL, the Page's ad ID, the platforms the ad runs on (Facebook feed, Instagram feed, Reels, Stories, Marketplace, Audience Network), and the start date the ad went live. You can see whether the ad is still active or has been paused. You can search by Page, by keyword, and filter by country and time window. That is the honest inventory of what the library shows for commercial healthcare ads in India — creative, copy, run dates, platforms, active status. It is a real corpus, and used well it is enormously informative.

What Meta Ad Library does not show — and why buyers keep getting misled

Everything money-shaped is missing. Meta does not publish, for commercial ads in India: total spend, spend range, impressions delivered, click-through rate, cost per click, cost per lead, conversion count, audience targeting parameters (age band, gender split, geography narrow-down, interest layers, custom audience source, lookalike source), placement performance by surface, or any signal about which creative variants outperformed inside an A/B split. None of it is visible.

The reason this matters: every tool that promises "see competitor spend" or "know competitor CPL" for commercial healthcare ads in India is inferring, sometimes competently and sometimes not. There is no data feed from Meta's backend to a third-party dashboard that carries these numbers. Any spend number on any external competitor tool for a commercial healthcare ad is a model output derived from public signals plus assumptions. Honest tools disclose the model; less honest ones present the estimate as if it were a measurement.

Political versus commercial transparency: the asymmetry buyers should understand

The confusion in most conversations about Meta transparency comes from conflating political ads with commercial ads. Political and social-issue ads in India (as in the US, EU, and other jurisdictions) carry additional disclosure — spend ranges, impression ranges, audience-reach breakdowns by state and demographic. This regime was introduced in 2019 following the political-advertising reforms and expanded since. It is why you can see actual spend ranges on Indian election ads and social-issue campaigns.

Commercial ads — the category every healthcare ad falls under — receive none of this expanded disclosure. Only the base library fields are shown. Buyers who read about Meta's "transparency" and expect the political-ad experience for a competitor IVF clinic are inevitably disappointed. The regulatory framing is different, and Meta's disclosure obligations are correspondingly narrower.

The India-specific transparency picture in 2026

India's transparency picture has three additional wrinkles beyond the global commercial baseline. First, the DPDP Act 2023 is now the operative data-protection regime and it affects both what advertisers can target and what third parties can observe about advertising audiences. Any competitor tool claiming targeting-level insight into commercial ads is skating close to the DPDP perimeter and should be treated with suspicion.

Second, healthcare-specific regulators overlay the commercial-advertising surface. The National Medical Commission (NMC) Ethics Code 2026, ASCI Guidelines 2022, PC-PNDT Act 1994 for prenatal diagnostics, and ART Act 2021 for fertility all constrain what a healthcare ad can claim regardless of what Meta's ad policy permits. Reading a competitor's ad through only the Meta lens misses the compliance signal an Indian healthcare team must also read.

Third, the Meta Ad Library's India catalogue is comprehensive on Pages that ran ads but incomplete on Pages that boosted individual posts below the boosted-content threshold. Small clinic operators sometimes assume their tactical boosts are invisible; above the threshold, they are not, and PrismSpy catches them in the daily refresh.

What you can legitimately infer from creative alone

The creative surface is thin on money but thick on strategy. From a competitor's active creatives you can legitimately infer: which service lines the brand is pushing (creative subject), which price points and offers are in market (offer text and CTA), which audience the creative is targeted at implicitly (language, imagery, tone), which format the brand is investing in (Reels-heavy vs static-heavy vs carousel-heavy), how fast the brand is refreshing (rolling creative age), which hooks are performing (longest-running ads that have survived the auction), and which offers have been withdrawn (past creatives that no longer appear active).

That set of inferences is enough to build a working picture of a competitor's Meta strategy over a quarter without touching a single number Meta withholds. A hair transplant chain running a three-week creative refresh cycle across 30+ Reels-first creatives is telling you a great deal about their playbook. An IVF clinic whose longest-running creative has been live for 140 days is telling you which hook they trust. This is the honest core of competitor intelligence.

What PrismSpy adds through structured tracking plus defensible inference

PrismSpy takes the public library surface and adds three layers no manual review can sustain. Layer one — structured longitudinal tracking. 75+ Indian healthcare brands watched daily, 2,150+ active ads catalogued, every creative's life-cycle recorded so an operator can query "show me every ad this brand has ever run in the derm cluster and when each was killed." The library itself does not preserve this history in a queryable structure; PrismSpy does.

Layer two — defensible inference. Estimated spend is derived from active-ad-day counts, format weighting and specialty CPM benchmarks calibrated against the live spend telemetry of ICG's Meta Catalyst IQ portfolio (23+ Indian healthcare accounts, ₹9.1Cr+ optimised spend per month). Estimated impression share follows the same modelled approach. Every number is labelled with its provenance so operators do not mistake inference for measurement.

Layer three — healthcare-specialty context. Ads are scored against NMC and ASCI perimeters, compliance-flagged where relevant, clustered by specialty (IVF, dermatology, dental, aesthetic, hair transplant, hospital and 24+ more), and cross-referenced against the 1,197 offers and 4,697 ad inspirations already in the PrismSpy corpus. The result is not "see everything Meta hides" — no responsible tool can promise that — it is "see everything Meta shows, structured for an Indian healthcare decision, with the inferences labelled."

Ethical limits: what PrismSpy deliberately does not try to do

The line between competitive intelligence and improper access matters and deserves saying out loud. PrismSpy does not scrape authenticated user data, does not use fake accounts to observe targeting-restricted ads, does not attempt to reverse-engineer a competitor's Business Manager, does not touch competitor CRM systems, does not exfiltrate lead-form submissions, and does not infer specific individual audiences from public signals. Every input is a public disclosure — Meta Ad Library, Google Ads Transparency Centre, brand landing pages, public offer schemas — and every output is labelled with its source.

Some tools cross these lines. Some vendors sell scraped user-level data or targeting inferences that were not obtained legitimately. Buying that data drags a healthcare marketing team into DPDP Act 2023 exposure with no meaningful upside — the intelligence a legitimate tool can provide from public sources is already sufficient for the decisions a healthcare marketing lead has to make. If a competitor-intelligence vendor cannot show you exactly how they obtained a number, treat the number as unusable.

DPDP Act 2023 and how it constrains what any tool should show you

The Digital Personal Data Protection Act 2023 restricts processing of personal data of Indian data principals. Applied to competitor intelligence, this means any inference tied to identifiable individuals — audiences reached, users retargeted, specific demographic clusters at fine granularity — sits inside the DPDP perimeter regardless of whether the aggregating tool is domestic or offshore. Aggregate, non-identifiable inferences (specialty-level SOV, brand-level creative counts, campaign-level spend estimates) are outside the perimeter because they don't reduce to individual data subjects.

PrismSpy's design line follows this distinction. Aggregate and brand-level analysis, yes. Individual-level or fine-grained demographic inference, no. Buyers evaluating any competitor tool should ask the same question: does what this tool shows me reduce to identifiable individuals? If yes, walk away. If no, the tool is on the right side of DPDP and the buyer is safe.

What competitor tools claim versus what they can actually verify

A working buyer checklist when evaluating any Meta competitor tool in India in 2026. Ask each vendor: is the spend number a measurement or a model — and if a model, is the methodology documented? Is the audience or targeting inference derived from public data, or from data of uncertain provenance? What is the refresh cadence — daily is table stakes, weekly is thin, monthly is stale? How many Indian healthcare brands are tracked specifically, and can you name the specialty clusters? Do you flag NMC / ASCI compliance signals on the creative you show? Are you DPDP-compliant by design or by afterthought?

Most global tools cannot answer these questions cleanly because they were built for a horizontal, English-first, global-brand buyer. That is not a criticism of the tools — they serve a real market — but it is a reason an Indian healthcare buyer needs a tool built for the actual perimeter it will operate in.

Powered by PrismSpy — every competitor Meta ad, watched daily

ICG built PrismSpy because Indian healthcare Meta ad competition is invisible without it. 75+ Indian healthcare brands tracked, 2,150+ active ads catalogued, ₹50Cr+ aggregate ad spend visibility per month. Every competitor ad — creative, offer, hook, run-length — refreshed daily. It runs underneath every Meta ads and performance marketing engagement at ICG.

• Watchlist Dashboard — 30-75 competitors per specialty cluster (IVF / dermatology / dental / hair transplant / aesthetic / hospital), daily refresh.
• Comparative Insights — highest-quality ads, longest-running creatives (proven converters), top hooks, emerging offers.
• Offers Intelligence — 1,197 offers tracked, discount intensity by brand, value tier distribution.
• Service Cluster + Inspirations — 419 services tracked, 4,697 searchable ad inspirations by hook / language / format.

Standalone from ₹4,999/- per specialty vertical, or bundled free inside HealthApex OS (₹14,999/- flat, 9 tools). Book a 30-min PrismSpy walkthrough on WhatsApp — Rohit + Hanuman walk you through your specialty's competitive landscape.

angryturtle/01-listing-overview.png" alt="Angryturtle Listing Overview — GBP watchlist with per-listing status, category, sub-scores, action count for 143+ managed Indian healthcare listings" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

Related reading

• Competitor share of voice for healthcare Meta ads in India
• Healthcare Meta ads agency India — pillar guide
• IVF marketing agency India
• Meta Catalyst IQ — the account-side platform
• Healthcare performance marketing service
• Request a free healthcare Meta ads audit

FAQ

Q. Can I see how much a competitor healthcare clinic is spending on Meta ads?
Not exactly. Meta does not publish spend for commercial ads in India — only political and social-issue ads carry spend ranges. Any commercial spend number you see on any tool is a model derived from public signals (active ad days, format mix, specialty CPM benchmarks). Treat it as a tier bucket, not an exact rupee figure.

Q. Can I see a competitor's cost per lead or click-through rate?
No. Meta does not publish account-level performance metrics — CPL, CPC, CTR, conversion rate — for commercial ads. These sit inside the competitor's Ads Manager and are not observable from outside. Any tool claiming otherwise is either inferring loosely or misrepresenting the data.

Q. Can I see who a competitor is targeting?
No. Audience-targeting parameters (age band, gender, geography narrow-down, interest layers, custom or lookalike audiences) are not published for commercial ads in India. Legitimate tools do not claim targeting-level inference for commercial healthcare ads.

Q. What can I actually see about a competitor's Meta ads in India?
The ad creative in full, the copy, the destination URL, the platforms it runs on, the start date, whether it is currently active or paused, and the advertising Page's verification status. That is the honest inventory. Structured over time and clustered by specialty, this is enough to build a working competitor read.

Q. Is it legal to research competitor ads using Meta Ad Library?
Yes. Meta Ad Library is a public disclosure surface, and competitive research using public data has been standard practice for decades. What is not legal, and not ethical, is scraping authenticated user data, using fake accounts to bypass targeting restrictions, or purchasing data of uncertain provenance from grey-market vendors.

Q. How does PrismSpy stay DPDP-compliant?
By design. Every input is a public disclosure — Meta Ad Library, Google Ads Transparency Centre, brand landing pages, public offer pages — and every output is aggregate or brand-level, not tied to identifiable individuals. No personal data of Indian data principals is processed. Independent DPDP review is offered to enterprise buyers on request.

Q. Does the Meta Ad Library show ads from Reels and Instagram Stories?
Yes, when a Page runs a structured ad campaign that includes those placements. The library shows the creative and lists all placements the ad is running on (Facebook feed, Instagram feed, Reels, Stories, Marketplace, Audience Network) as declared in the campaign.

Q. What is the single most useful thing to look at inside Meta Ad Library for a healthcare competitor?
Longest-running ads. A creative that has been live for 60+ days without being paused is one the competitor's account team has decided is worth continuing to fund — which is a proxy for it converting. That short list, refreshed weekly, is a stronger read on a competitor's working creative than any spend estimate.

For the underlying disclosure surface, see Meta's Ad Library and Meta's Ad Library reference documentation.